Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...

Panelists discuss how EGFR-targeted therapies differ in administration protocols and management strategies, with Palmer sharing tailored nursing interventions for oral tyrosine kinase inhibitors (TKIs ...

Panelists discuss how dermatologic toxicities from EGFR-targeted therapies can be effectively managed through a comprehensive approach combining prophylactic measures, early interventions with oral ...

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

"When most people hear the words palliative care, they immediately think about hospice or end-of-life care. This includes ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to ...

Baseline ctDNA presence was associated with larger tumor size and higher residual disease burden scores following neoadjuvant endocrine therapy in HR-positive, early breast cancer.

ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...

ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...